|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,916.00 GBX | -0.60% |
|
+0.94% | +5.65% |
| 10/08 | WINNERS & LOSERS: Threat to Vistry; Plus500 plans more share buybacks | AN |
| 07/08 | LifeMine Therapeutics, Inc. announced that it has received $188 million in funding from a group of investors | CI |
| Market Cap | 77.24B 104B 90.41B 84.51B 146B 9,961B 148B 991B 389B 4,983B 392B 384B 16,596B | P/E 2026 * |
13.9x | P/E 2027 * | 11.6x |
|---|---|---|---|---|---|
| Enterprise Value | 96.32B 130B 113B 105B 182B 12,421B 184B 1,236B 485B 6,214B 489B 478B 20,696B | EV / Sales 2026 * |
2.84x | EV / Sales 2027 * | 2.63x |
| Free-Float |
92.75% | Yield 2026 * |
3.61% | Yield 2027 * | 3.89% |
Last Transcript: GSK plc
| 1 day | -1.68% | ||
| 1 week | +0.94% | ||
| Current month | -0.21% | ||
| 1 month | -1.73% | ||
| 3 months | +4.58% | ||
| 6 months | -11.09% | ||
| Current year | +5.65% |
| 1 week | 1,904 |  | 1,972 |
| 1 month | 1,850.5 | | 2,096 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/7/26 | Sell | Executive/Senior Manager | -38,000 | 0.0009% | ||
| 22/7/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 14/7/26 | Buy | Chief Technology Officer | 660 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.58% | +0.94% | +38.12% | +38.91% | 104B | |
| +3.90% | +9.86% | +96.91% | +136.30% | 1,098B | |
| +0.99% | +2.91% | +51.05% | +52.06% | 631B | |
| +0.78% | +1.17% | +25.21% | +63.74% | 438B | |
| -0.01% | +4.80% | +51.42% | +39.79% | 368B | |
| +0.32% | +1.85% | +34.81% | +39.99% | 298B | |
| -0.53% | +4.26% | +9.78% | +7.42% | 251B | |
| +1.52% | +10.12% | +44.75% | +59.20% | 226B | |
| +1.09% | +1.27% | -5.23% | -50.94% | 209B | |
| -0.11% | +1.46% | +11.43% | +66.32% | 165B | |
| Average | +0.88% | +2.86% | +35.82% | +45.28% | 378.88B | |
| Weighted average by Cap. | +1.70% | +4.70% | +51.81% | +67.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.95B 45.91B 39.75B 37.15B 63.98B 4,379B 64.98B 436B 171B 2,191B 172B 169B 7,296B | 35.6B 48.13B 41.67B 38.95B 67.08B 4,590B 68.13B 457B 179B 2,297B 181B 177B 7,649B |
| Net income | 5.76B 7.78B 6.74B 6.3B 10.85B 742B 11.01B 73.84B 28.98B 371B 29.22B 28.58B 1,237B | 6.7B 9.05B 7.84B 7.33B 12.62B 864B 12.82B 85.91B 33.71B 432B 34B 33.26B 1,439B |
| Net Debt | 19.08B 25.8B 22.34B 20.88B 35.96B 2,461B 36.52B 245B 96.06B 1,231B 96.88B 94.77B 4,100B | 16.24B 21.96B 19.01B 17.77B 30.6B 2,094B 31.08B 208B 81.76B 1,048B 82.46B 80.66B 3,490B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/08/26 | GBX 1,918.50 | -0.47% | 189,675 |
| 10/08/26 | GBX 1,927.50 | -1.68% | 5,929,763 |
| 07/08/26 | GBX 1,960.50 | +1.24% | 4,447,941 |
| 06/08/26 | GBX 1,936.50 | +1.10% | 3,139,064 |
| 05/08/26 | GBX 1,915.50 | +0.05% | 8,739,818 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
